<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case is presented of a 73-year-old woman who received busulphan for <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> and subsequently developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), which transformed to <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> within 1 month </plain></SENT>
<SENT sid="1" pm="."><plain>Cytogenetic studies showed a 46,XX,t(8;21) (q22;q22) karyotype in <z:hpo ids='HP_0000001'>all</z:hpo> metaphases examined at diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>The karyotypic abnormality is previously unreported in secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and may have specific clinical implications in this setting, such as early transformation to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and short survival </plain></SENT>
<SENT sid="3" pm="."><plain>This finding contrasts with the generally favourable prognosis of the 8;21 translocation in patients with de novo <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A possible explanation for this difference may be the involvement of a committed progenitor in <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, while in <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> the more primitive multipotent stem cell may be affected </plain></SENT>
</text></document>